Blueshift Asset Management, LLC United Therapeutics Corp Transaction History

Blueshift Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$214.88 - $256.94 $426,107 - $509,512	1,983 New	1,983 $436,000
Q2 2023 Aug 15, 2023	BUY	$205.19 - $232.99 $8,617 - $9,785	42 Added 2.97%	1,458 $321,000
Q1 2023 May 12, 2023	BUY	$212.99 - $276.17 $301,593 - $391,056	1,416 New	1,416 $317,000
Q4 2021 Feb 11, 2022	SELL	$184.32 - $216.08 $723,271 - $847,897	-3,924 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$179.86 - $214.88 $216,191 - $258,285	1,202 Added 44.16%	3,924 $724,000
Q2 2021 Aug 13, 2021	BUY	$170.47 - $211.93 $464,019 - $576,873	2,722 New	2,722 $488,000
Q3 2019 Nov 12, 2019	SELL	$74.85 - $85.99 $389,444 - $447,405	-5,203 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$76.06 - $120.81 $395,740 - $628,574	5,203 New	5,203 $406,000

681

42.2M

194K

298K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Blueshift Asset Management, LLC with notifications on news.